dimethyl fumarate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 27 Diseases   27 Trials   27 Trials   3795 News 


«12345678910111213...4546»
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Tysabri (natalizumab) / Biogen, Royalty
    Journal:  Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. (Pubmed Central) -  Jun 26, 2024   
    She was treated with plasma exchange and then corticosteroids for PML immune reconstitution inflammatory syndrome before starting glatiramer acetate for DMT...Owing to worsening footdrop consistent with progression, she transitioned to ocrelizumab in 2017 and then to ofatumumab in 2020 due to logistics of medication administration...This provides Class IV evidence. It is a single observational study without controls.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Monosodium Urate Crystal-Induced Pyroptotic Cell Death in Neutrophil and Macrophage Facilitates the Pathological Progress of Gout. (Pubmed Central) -  Jun 5, 2024   
    Based on these mechanistic understandings, it is shown that N-GSDMD oligomerization inhibitor, dimethyl fumarate (DMF), inhibits MSU crystal-induced pyroptosis in BMNs and J774A.1 cells, and it further alleviates the acute inflammatory response in MSU crystals-induced gout mice model. This study elucidates that MSU crystal-induced pyroptosis in neutrophil and macrophage is critical for the pathological progress of gout, and provides a new therapeutic approach for the treatment of gout.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Journal, Real-world evidence, Real-world:  TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time. (Pubmed Central) -  May 29, 2024   
    Among the latter, previous DMTs were interferon (21%), glatiramer acetate (11%), and dimethyl fumarate (9%), and reasons for discontinuation were adverse events (AEs; 55%) and insufficient efficacy (16%)...Tolerability was comparable to previous trials. Bundesinstitut f
  • ||||||||||  Fumaderm (dimethyl fumarate) / Biogen
    Journal, HEOR, Real-world evidence, Real-world:  Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. (Pubmed Central) -  May 27, 2024   
    To use MSBase registry data to compare real-world outcomes in adults with relapsing-remitting MS (RRMS) treated with dimethyl fumarate (DMF) or NSIS (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mitoxantrone or mycophenolate mofetil) between January 1, 2014 and April 1, 2022...The DMF cohort experienced longer times to discontinuation (HR: 0.75; p?=?0.001) and CDP (HR: 0.53; p?=?0.001), and shorter time to CDI (HR: 1.99; p?<?0.008), versus the NSIS cohort. This analysis supports the use of DMF to treat patients with relapsing forms of MS, and may have implications for MS practices in countries where NSIS are commonly used to treat RRMS.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Evaluation of the effect of dimethyl fumarate on human bone marrow-derived mesenchymal stem cells using bottom-up proteomics. (Pubmed Central) -  May 23, 2024   
    Pathway enrichment analysis suggested a possible decrease in autophagy and a decrease in the activity of the TCA cycle, while indicating a potential increase in proliferation and antioxidant activity in DMF-treated MSCs compared to untreated MSCs. Our findings suggest that DMF can enhance the proliferation of MSCs and increase their stability, and that preconditioning could improve the therapeutic efficacy of MSCs for the treatment of regenerative diseases.
  • ||||||||||  Bafiertam (monomethyl fumarate) / Thermo Fisher Scientific
    Review, Journal:  The Evolving Role of Monomethyl Fumarate Treatment as Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis. (Pubmed Central) -  May 7, 2024   
    Several different drugs have been recently approved for use in modifying the course of the disease, including a group of medications known as fumarates (e.g., dimethyl fumarate, diroximel fumarate, monomethyl fumarate) that have been shown to be efficacious and relatively safe. In the present investigation, we review available evidence focused on monomethyl fumarate, also known as Bafiertam
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Enrollment closed:  DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) -  May 1, 2024   
    P4,  N=800, Active, not recruiting, 
    in this multicenter study that included 269 patients from Argentina we observed in early HET a significantly lower BOT and higher QoL than patients receiving escalation therapy. Recruiting --> Active, not recruiting
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Chaperone-mediated autophagy protects against hyperglycemic stress. (Pubmed Central) -  Apr 29, 2024   
    Finally, we demonstrated that CMA plays an important protective role against HG-induced stress, primarily mediated by one of the two RT Lamp2As. Together, our results provide unequivocal evidence for CMA activity existence in RT and highlight both the role and regulation of CMA during glucose-related metabolic disorders.
  • ||||||||||  Promoting generic multiple sclerosis drug utilization and drug cost savings with a managed care pharmacist outreach program () -  Apr 9, 2024 - Abstract #AMCP2024AMCP_113;    
    An automated analytic rule process using claims data and providing MCP with actionable information successfully converted 16% of MS brand to generic thera- py cases, resulting in $9 million validated savings, with an additional $11 million savings potential among in-progress cases. Using a web application to facilitate MCP outreach can aid in transitioning to generic therapy, reducing total MS drug spend and member cost.
  • ||||||||||  Journal:  Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs. (Pubmed Central) -  Mar 29, 2024   
    Notably, 218 patients (62.4% females) initiating dimethyl fumarate, teriflunomide, and fingolimod were included...RS, mRS, and MAGNIMS 0 categories showed significantly lower EDA and treatment failure than the remainder. Scoring systems present different predictive abilities for disease activity parameters at 36?months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.
  • ||||||||||  Retrospective data, Journal:  Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework. (Pubmed Central) -  Mar 26, 2024   
    This retrospective cohort study used administrative claims data to derive four cohorts of adults with multiple sclerosis initiating dimethyl fumarate, teriflunomide, glatiramer acetate or fingolimod between January 2013 and December 2018...This study effectively demonstrated the use of an innovative statistical methodology to test a clinical hypothesis using real-world data to perform early target validation for drug discovery. Although there was a trend among patients treated with dimethyl fumarate towards a decreased incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease relative to other disease-modifying therapies-which was statistically significant for the comparison with teriflunomide-this study did not definitively support the hypothesis that Nrf2 activation provided additional metabolic disease benefit in patients with multiple sclerosis.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Preclinical, Journal:  Neuroprotective effects of rutin against cuprizone-induced multiple sclerosis in mice. (Pubmed Central) -  Mar 21, 2024   
    Findings of the current study provide evidence for the protective effect of RUT in CPZ-induced demyelination and behavioral dysfunction in mice, possibly by modulating NF-?B and Nrf2 signaling pathways. The present study may be one of the first to indicate a pro-remyelinating effect for RUT, which might represent a potential additive benefit in treating MS.
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Review, Journal:  Radiologically isolated syndromes: to treat or not to treat? (Pubmed Central) -  Mar 19, 2024   
    Recent randomized controlled trials conducted in individuals with RIS have shown that dimethyl fumarate and teriflunomide significantly reduce the occurrence of clinical events in this population...However, several aspects should be taken into account before treating individuals with RIS in the real-world clinical setting, including an accurate identification of individuals with RIS to avoid misdiagnosis, a precise stratification of their risk of experiencing a first clinical event and further data supporting favorable balance between benefits and risks, even in the long term. This commentary provides an overview of the latest updates in RIS diagnosis, prognosis, and emerging treatment evidence.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Self-adaptive pyroptosis-responsive nanoliposomes block pyroptosis in autoimmune inflammatory diseases. (Pubmed Central) -  Mar 18, 2024   
    Therefore, RC-NL@DMF exhibited effective therapeutic efficacies to alleviate autoimmune inflammatory damages in zymosan-induced arthritis mice and dextran sulfate sodium-induced inflammatory bowel disease mice. Our novel approach holds great promise for self-adaptive pyroptosis-responsive on-demand drug delivery, suppressing pyroptosis and treating autoimmune inflammatory diseases.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Intraarticular monomethyl fumarate as a perspective therapy for osteoarthritis by macrophage polarization. (Pubmed Central) -  Mar 13, 2024   
    Regnase-1 could be a novel potential therapeutic target in colon tumors. Our studies with EOA model induced by MIA suggest a new perspective for human treatment committed with OA based on macrophage polarization as a therapeutic target, switching the proinflammatory profile M1 to the anti-inflammatory profile M2 with DMF systematic or by MMF locally treatment according to the OA severity.
  • ||||||||||  IMCY-0141 / Imcyse
    Enrollment closed:  IMCY-MS-001: IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study (clinicaltrials.gov) -  Mar 12, 2024   
    P1/2,  N=150, Active, not recruiting, 
    Our studies with EOA model induced by MIA suggest a new perspective for human treatment committed with OA based on macrophage polarization as a therapeutic target, switching the proinflammatory profile M1 to the anti-inflammatory profile M2 with DMF systematic or by MMF locally treatment according to the OA severity. Recruiting --> Active, not recruiting
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Journal:  Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report. (Pubmed Central) -  Mar 9, 2024   
    After 1.5 years of treatment with dimethyl fumarate (DMF) for multiple sclerosis, preceded 8 years earlier by intravenous (IV) cladribine and 1 year earlier by natalizumab, our patient developed myelodysplastic syndrome (MDS)...Repeat bone marrow biopsy demonstrated a new unbalanced translocation (between the chromosome 1 long arm and chromosome 7 short arm). This case report, to our knowledge, is the first linking iatrogenic MDS to DMF and cladribine, while also suggesting caution with immunosuppressants in multiple sclerosis patients.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    MULTIPLE SCLEROSIS INDUCED RHABDOMYOLYSIS INDUCED ACUTE KIDNEY INJURY (TUE-019; Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_631;    
    Early adverse events and pregnancy were the main reasons provided for discontinuing DMF therapy. We present a case of severe acute renal injury linked with rhabdomyolysis caused by severe multiple sclerosis, with a favorable prognosis.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (Colorado Convention Center | Mile High 2/3) -  Mar 8, 2024 - Abstract #AAN2024AAN_4340;    
    Patients who developed disease activity after discontinuing DMD were younger (mean age 48)compared to patients who remained with no disease activity (mean age 60) and had loweraverage EDSS scores (2.8 vs 3.58). Patients who discontinued fingolimod and natalizumab wereat higher risk of disease activity after treatment discontinuation (58% and 30%, respectively).Finally, patients > 60 years and EDSS > 6 were at the lowest risk of disease activity afterdiscontinuation.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Treatment Persistence of Cladribine Tablets Versus Other Oral Disease-modifying Treatments for Multiple Sclerosis: Results from Danish, Norwegian, and Swedish Registries (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_4151;    
    Patients who discontinued fingolimod and natalizumab wereat higher risk of disease activity after treatment discontinuation (58% and 30%, respectively).Finally, patients > 60 years and EDSS > 6 were at the lowest risk of disease activity afterdiscontinuation. Objective:Compare real-world time-to-treatment switch and discontinuation in adult patients receiving cladribine tablets (CladT; 3.5mg/kg cumulative dose over 2 years) versus other oral disease-modifying therapies (DMTs).Background:Generating Learnings In MultiPle SclErosis (GLIMPSE) is a longitudinal study of prospectively collected registry data to compare real-world treatment outcomes in patients with relapsing multiple sclerosis treated with CladT versus other oral DMTs (fingolimod [FING], dimethyl fumarate (DMF), and teriflunomide [TER]).Design/Data from Danish, Norwegian, and Swedish multiple sclerosis registries were pooled for treatment-na
  • ||||||||||  Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
    Change in Disease Modifying Therapy from DMF to DRF in People with Multiple Sclerosis and the Impact on CD4/CD8 T Cells (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3938;    
    PwMS who switched from DMF to DRF showed a statistically significant decrease in CD8 T cell count over 1 year of treatment, with the shift becoming evident after 3 months of treatment. Changes in T cell subsets in patients treated with DRF were not associated with an increase in infections.
  • ||||||||||  Ocrevus (ocrelizumab) / Roche, Biogen
    Ocrelizumab in Patients With Early-stage RRMS (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3219;    
    P3
    The study is limited by the short observation period while non-disabling relapses are frequent in early RRMS. The ITT approach accounted for the real-world treatment pathways and DMT switches; however, it may not fully account for the effect on disability worsening of escalation strategy to high-efficacy DMTs applied in NTD.